Quantcast

Latest Ipilimumab Stories

2009-02-25 07:00:00

MOUNTAIN VIEW, California, February 25 /PRNewswire/ -- BN ImmunoTherapeutics, Inc. announced today that the first detailed data on PROSTVAC(TM) since the vaccine was licensed from the National Institutes of Health (NIH) is now available.

2009-01-28 07:00:00

PRINCETON, N.J., Jan. 28 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today the allowance of an investigational new drug (IND) application filed with the U.S.

2009-01-19 07:00:00

Ipilimumab Will Earn Decision Resources' Clinical Gold Standard for Stage IV Malignant Melanoma in 2012, According to a New Report from Decision Resources WALTHAM, Mass., Jan.

2009-01-13 11:09:00

PRINCETON, N.J., Jan. 13 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today provided an overview of the company's strong science-base and strategy for maximizing the value of its product portfolio.

2008-11-04 12:00:05

Medarex, a biopharmaceutical company, and The Massachusetts Biologic Laboratories of the University of Massachusetts Medical School have announced that a Phase II trial of an anti-C difficile antibody combination treatment in patients with C difficile associated diarrhea successfully met its primary objective.

2008-11-03 09:00:06

PRINCETON, N.J. and JAMAICA PLAIN, Mass., Nov. 3 /PRNewswire-FirstCall/ -- Medarex, Inc. and The Massachusetts Biologic Laboratories (MBL) of the University of Massachusetts Medical School (UMMS) today announced that a Phase 2 trial of an anti-C.

2008-10-23 09:00:38

Poniard Pharmaceuticals, a biopharmaceutical company focused on oncology, has announced positive incremental data from its ongoing Phase II clinical trial of picoplatin in combination with docetaxel and prednisone as first-line therapy for metastatic hormone-refractory prostate cancer.

2008-09-16 12:00:49

Bristol-Myers Squibb Company and Medarex have announced updated survival data from three Phase II studies of ipilimumab in patients with advanced metastatic melanoma who had previously been treated.

2008-09-15 12:00:09

Bristol-Myers Squibb Company (NYSE: BMY) and Medarex, Inc. (NASDAQ: MEDX) today announced updated survival data from three Phase 2 studies of ipilimumab in patients with advanced metastatic melanoma (Stage III or IV) who had previously been treated.

2008-08-28 06:00:18

OSLO, August 28 /PRNewswire-FirstCall/ -- - Results Further Support the Clinical Profile of This Novel Anti-Cancer Agent Under Development to Improve the Survival of Patients With Hormone Refractory Prostate Cancer (HRPC) Algeta ASA , the Norwegian cancer therapeutics company, today announced that the primary objective of its BC1-03 Phase II pain palliation study was met.


Word of the Day
  • an ornament or knob in the shape of a flower
  • In architecture, a floral ornament; specifically, the large conventional flower usually placed in the center of the abacus of a Corinthian capital or classic ceiling-caisson; also, the floreated termination of a Gothic finial.
[ "The word 'fleuron' comes from French."]